The cannabinoid story is hardly new to biopharma. The first cannabinoid therapeutics were approved roughly two decades ago, but only four drugs targeting the brain's cannabinoid receptors have made it to market, targeting narrow indications associated with cancer, neuropathic pain, chemotherapy-induced nausea and vomiting (CINV) or cachexia. Read More
